Skip to main content

Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An Author's Perspective
    • Ask the Experts
    • Bioanalysis articles
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Spotlights
    • Tech Digest
    • T&F journals

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Awareness
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Professional development
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Biosensors
      • Chromatography
      • Flow Cytometry
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register

The technology behind Bio-Rad’s custom recombinant antibodies

25 Oct 2017
Antibodies | ADCs

Take a look inside Bio-Rad’s custom recombinant antibody facility. Learn from our antibody experts how your requirements for specialized anti-biotherapeutic antibodies can become a reality through the use of HuCAL technology.


For more information on Bio-Rad, please click here.

Top content

  • Highlights from the 20th WRIB
  • Stretching the limit: new technique improves measurement of cell elasticity
  • Sapient introduces tumor protein mapping platform

Related tags

antibody Bio-rad biotherapeutics technology
Previous article Next article

Related articles

28 NOV 2014 GENERAL INTEREST
New acoustic sensor shows promise for biological and chemical analysis
12 NOV 2014 GENERAL INTEREST
EBF Lecture: How alternative bioanalytical technologies can assist clinical safety and efficacy assessment
23 JAN 2014 GENERAL INTEREST
Scientists develop new biosensor to test for Alzheimer’s disease
Using hydrogels for aptamer selection
18 OCT 2023 NEWS
Finding a needle in a haystack: aptamer screening using hydrogels
13 MAY 2014 GENERAL INTEREST
Collaborative research initiative for tumor profiling
28 AUG 2017 NEWS
Immune regulatory cells could act as biomarkers to diagnose autoimmune diseases
  • About
  • Accessibility
  • Advertising & Sponsorship
  • Contact Us
  • Editorial Policies
  • Permissions
  • Whitelist Emails
  • Zone Leaders

Contact

Contact Us

Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2026 Bioanalysis Zone